Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to -$2.1 million.

  • Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities rose 2270.55% to -$2.1 million in Q2 2025 from the same period last year, while for May 2025 it was -$6.4 million, marking a year-over-year increase of 6512.64%. This contributed to the annual value of -$6.4 million for FY2025, which is 6512.64% up from last year.
  • Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities amounted to -$2.1 million in Q2 2025, which was up 2270.55% from $1.5 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities peaked at $65.2 million during Q1 2022, and registered a low of -$17.5 million during Q2 2022.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median Cash from Investing Activities value was -$3.6 million (recorded in 2022), while the average stood at $1.8 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities skyrocketed by 13960740.74% in 2021, and later plummeted by 213628.32% in 2023.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Cash from Investing Activities (Quarter) stood at -$5.4 million in 2021, then grew by 29.06% to -$3.8 million in 2022, then fell by 10.73% to -$4.3 million in 2023, then soared by 42.74% to -$2.4 million in 2024, then rose by 14.06% to -$2.1 million in 2025.
  • Its last three reported values are -$2.1 million in Q2 2025, $1.5 million for Q1 2025, and -$2.4 million during Q4 2024.